請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21394完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 廖泰慶,王尚麟 | |
| dc.contributor.author | Ching-Tien Tseng | en |
| dc.contributor.author | 曾靖恬 | zh_TW |
| dc.date.accessioned | 2021-06-08T03:32:52Z | - |
| dc.date.copyright | 2019-08-15 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-08-07 | |
| dc.identifier.citation | 1.Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv Antibody: Principles and Clinical Application. Clin Dev Immunol 2012, 2012.
2.Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. Oncol Rep 32: 159-166, 2014. 3.Archer CW, Morrison H, Pitsillides AA. Cellular aspects of the development of diarthrodial joints and articular cartilage. J Anat 184 ( Pt 3): 447-456, 1994. 4.Areshkov PO, Avdieiev SS, Balynska OV, Leroith D, Kavsan VM. Two closely related human members of chitinase-like family, CHI3L1 and CHI3L2, activate ERK1/2 in 293 and U373 cells but have the different influence on cell proliferation. Int J Biol Sci 8: 39-48, 2012. 5.Armand S, Tomita H, Heyraud A, Gey C, Watanabe T, Henrissat B. Stereochemical course of the hydrolysis reaction catalyzed by chitinases A1 and D from Bacillus circulans WL-12. FEBS Lett 343: 177-180, 1994. 6.Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 11: 559-595, 2004. 7. Boisen MK, Madsen CV, Dehlendorff C, Jakobsen A, Johansen JS, Steffensen KD. The prognostic value of plasma ykl-40 in patients with chemotherapy-resistant ovarian cancer treated with bevacizumab. Int J Gynecol Cancer 26(8): 1390-1398, 2016. 8. Bostock DE: Neoplasms of the skin and subcutaneous tissues in dogs and cats, Br Vet J 142:1-19, 1986. 9. Brodey RS, Riser WH: Canine osteosarcoma. A clinicopathologic study of 194 cases, Clin Orthop 62:54-64, 1969. 10. Boot, R.G.; van Achterberg, T.A.E.; van Aken, B.E.; Renkema, G.H.; Jacobs, M.J.H.M.; Aerts, J.M.F.G.; de Vries, C.J.M. Strong induction of members of the chitinase family of proteins in atherosclerosis. Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. 19, 687–694, 1999. 11. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocrinol Metab. 2011;96:200–209. 12. Cheng K-J, Engineering of Canine YKL-40 scFv Antibodies for Canine Cancer Research, M.S. thesis, National Taiwan University, Taiwan, 2018. 13. Cheng K-C, Development and Characterization of Canine YKL-40 Monoclonal Antibody for Canine Cancer Research, M.S. thesis, National Taiwan University, Taiwan, 2015. 14. Co-operative Oncology Group (VCOG) Consensus Document, Vet Comp Oncol 8(1):28–37, 2010. 15. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 132: 2339-2348, 2013. 16. Chudecka-Glaz A, Gorski B, Zielinska D, Blogowski W, Wojciechowska I, Bedner R, Rzepka-Gorska I. Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen. Eur J Gynaecol Oncol 30: 668-671, 2009. 17. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 79: 1494-1499, 1999. 18. Conroy AL, Hawkes MT, Elphinstone R, Opoka RO, Namasopo S, Miller C, John CC, Kain KC. Chitinase-3-like 1 is a biomarker of acute kidney injury and mortality in paediatric severe malaria. Malaria Journal 17: 11, 2018. 19. Dank G, Rassnick KM, Sokolovsky Y, Garrett LD, Post GS, Kitchell BE, Sellon RK, Kleiter M, Northrup N, Segev G. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision.Vet Comp Oncol 12: 78-84, 2014. 20. Di Rosa M, Distefano G, Zorena K, Malaguarnera L. Chitinases and immunity: Ancestral molecules with new functions. Immunobiology 221: 399-411, 2016. 21. Di Rosa M, Malaguarnera G, De Gregorio C, Drago F, Malaguarnera L. Evaluation of CHI3L-1 and CHIT-1 Expression in Differentiated and Polarized Macrophages. Inflammation 36: 482-492, 2013. 22. Diaz-Lagares A, Alegre E, Arroyo A, Gonzalez-Cao M, Zudaire ME, Viteri S, Martin-Algarra S, Gonzalez A. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 32: 1155-1161, 2011. 23. Dolezal O, Pearce LA, Lawrence LJ, McCoy AJ, Hudson PJ, Kortt AA. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V-L to V-H orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Engineering 13: 565-574, 2000. 24. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40: 307-318, 1968. 25. Edwards DS, Henley WE, Harding EF, Dobson JM, Wood JL. Breed incidence of lymphoma in a UK population of insured dogs. Vet Comp Oncol 1: 200-206, 2003. 26. Reed JH. The occurrence of tumors in domestic animals. Can Vet J 23: 71, 1982. 27. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 10: 742-751, 2011. 28. Francescone RA. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 286, 2011. 29. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 278, 2003 30. Finnie JW, Bostock DE: Skin neoplasia in dogs, Aust Vet J 55:602-604, 1979. 31. Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 104:1204–1210, 2010. 32. Goldschmidt M.H., Hendrick M.J. Tumors of the skin and soft tissues. In: Meuten D.J., editor. Tumors in Domestic Animals. 4th ed. Iowa State Press; Ames, IA, USA . pp. 78–82, 2002. 33. Gu X, Jia X, Feng J, Shen B, Huang Y, Geng S, Sun Y, Wang Y, Li Y, Long M. Molecular Modeling and Affinity Determination of scFv Antibody: Proper Linker Peptide Enhances Its Activity. Annals of Biomedical Engineering 38: 537-549, 2010. 34. Guo JQ, You SY, Li L, Zhang YZ, Huang JN, Zhang CY. Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli. J Biotechnol 102: 177-189, 2003. 35. Grønlund, B.; Høgdall, E.V.S.; Christensen, I.J.; Johansen, J.S.; Nørgaard-Pedersen, B.; Engelholm, S.A.; Høgdall, C. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125). Int. J. Biol. Markers 21, 141–148, 2006. 36. Hakala, B.E.; White, C.; Recklies, A.D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. 268, 25803–25810, 1993. 37. Haidaris CG, Malone J, Sherrill LA, Bliss JM, Gaspari AA, Insel RA, Sullivan MA. Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens. J Immunol Methods 257: 185-202, 2001. 38. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268, 1993. 39. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell 144: 646-674. 40. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, Swindlehurst C. Chondrex: new marker of joint disease. Clin Chem 44: 509-516, 1998. 41. Hogdall EV, Ringsholt M, Hogdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Moller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 9: 8, 2009. 42. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19: 4133-4137, 1991. 43. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12: 5698-5704, 2006. 44. Hou S, Isaji T, Hang Q, Im S, Fukuda T, Gu J. Distinct effects of β1 integrin on cell proliferation and cellular signaling in MDA-MB-231 breast cancer cells. Sci Rep 6, 2016. 45. Howlett AR, Bailey N, Damsky C, Petersen OW, Bissell MJ. Cellular growth and survival are mediated by beta 1 integrins in normal human breast epithelium but not in breast carcinoma. J Cell Sci 108 ( Pt 5): 1945-1957, 1995. 46. Huang W-H, Liao AT, Chu P-Y, Zhai S-H, Yen IF, Liu C-H. A 3-year surveillance on causes of death or reasons for euthanasia of domesticated dogs in Taiwan. Preventive Veterinary Medicine 147: 1-10, 2017. 47. Hust M, Jostock T, Menzel C, Voedisch B, Mohr A, Brenneis M, Kirsch MI, Meier D, Dübel S. Single chain Fab (scFab) fragment. BMC Biotechnol 7: 14, 2007. 48. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 13: 1244-1251, 2011. 49. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53: 172- 209, 2006. 50. Johansen JS, Christensen IJ, Jorgensen LN, Olsen J, Rahr HB, Nielsen KT, Laurberg S, Brunner N, Nielsen HJ. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 24: 621-626, 2015. 51. Johansen JS, Hoyer PE, Larsen LA, Price PA, Mollgard K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 55, 2007. 52. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15: 194-202, 2006. 53. Johansen JS, Moller S, Price PA, Bendtsen F, Junge J, Garbarsch C, Henriksen JH. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 32: 582-590, 1997. 54. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 5: 1065-1082, 2009. 55. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res. 9:4423–34, 2003. 56. Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998–2000). J Vet Med Ser A 49: 419-424, 2002. 57. Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 35: 277-286, 2014. 58. Kawada M, Seno H, Kanda K, Nakanishi Y, Akitake R, Komekado H, Kawada K, Sakai Y, Mizoguchi E, Chiba T. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31: 3111-3123, 2012. 59. Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. Stroke 46: 329-335, 2015a. 60. Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Crit Rev Clin Lab Sci 53: 396-408, 2016. 61. Kjaergaard AD, Nordestgaard BG, Johansen JS, Bojesen SE. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int J Cancer 137: 2696-2704, 2015b. 62. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, Pluckthun A. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 201: 35-55, 1997. 63. Ku BM, Lee YK, Ryu J, Jeong JY, Choi J, Eun KM. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 128, 2011. 64. Kzhyshkowska J, Yin S, Liu T, Riabov V, Mitrofanova I. Role of chitinase-like proteins in cancer. Biol Chem 397: 231-247, 2016. 65. Krogh, M.; Christensen, I.J.; Bouwhuis, M.; Johansen, J.S.; Schmidt, H.; Hansson, J.; Aamdal, S.; Testori, A.; Eggermont, A.M.; Bastholt, L. Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy. ASCO Ann. Meet. Proc. Abstract 8587, 2010. 66. Lawrence J, Vanderhoek M, Barbee D, et al: Use of 3′-deoxy-3′-[18F] fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin’s lymphoma, Vet Radiol Ultrasound 50:660–668, 2009. 67. Lin C-Y, Recombinant Canine YKL-40 Expression and Its Effects on Canine Mammary Gland Tumor Cells, M.S. thesis, National Taiwan University, Taiwan, 2013. 68. Low D, Subramaniam R, Lin L, Aomatsu T, Mizoguchi A, Ng A, DeGruttola AK, Lee CG, Elias JA, Andoh A, Mino-Kenudson M, Mizoguchi E. Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9. Oncotarget 6: 36535-36550, 2015. 69. LeBlanc AK, Jakoby BW, Townsend DW, et al: 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor, Vet Radiol Ultrasound 50(2):215–223, 2009. 70. London CA, Thamm DH. Mast cell tumors. In: Withrow SJ, Vail DM, and Page RL, ed. Withrow and MacEwen's small animal clinical oncology. 5th ed. Elsevier Saunders, St. Louis, 335-355, 2013. 71. Malik P, Chaudhry N, Mittal R, Mukherjee TK. Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. Biochim Biophys Acta 1850: 1898-1904, 2015. 72. Muszynski P, Groblewska M, Kulczynska-Przybik A, Kulakowska A, Mroczko B. YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease. Curr Neuropharmacol 15: 906-917, 2017. 73. Morrison BW, Leder P. Neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene. 1994;9(12):3417–3426. 74. Marconato L, Crispino G, Finotello R, et al: Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma, J Am Vet Med Assoc 236:969–974, 2010. 75. Nielsen L, Toft N, Eckersall PD, et al: Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma, J Vet Intern Med 21:1231–1236, 2007. 76. Northrup, NC, Harmon, BG, Gieger, TL, Brown, CA, Carmichael, KP, Garcia, A, Latimer, KS, Munday, JS, Rakich, PM, Richey, LJ, Stedman, NL, Cheng, AL, Howerth, EW: Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest 17:245–248, 2005. 77. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 27: 331-337, 2009. 78. Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19: 257-263, 2008. 79. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 287:79–87, 2003. 80. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66: 1526-1535, 2006. 81. Park HY, Jun CD, Jeon SJ, Choi SS, Kim HR, Choi DB, Kwak S, Lee HS, Cheong JS, So HS, Lee YJ, Park DS. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 7: e51722, 2012. 82. Qureshi AM, Hannigan A, Campbell D, Nixon C, Wilson JB. Chitinase-like proteins are autoantigens in a model of inflammation-promoted incipient neoplasia. Genes Cancer 2: 74-87, 2011. 83. Rajawat R, Narkar A, Damle A, Kumar GB, Mishra KP. A single-chain antibody fragment against human thyroglobulin: construction and evaluation of immunoreactivity. Hybridoma (Larchmt) 30: 253-259, 2011. 84. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39(CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43, 1997. 85. Roslind A, Knoop AS, Jensen MB, Johansen JS, Nielsen DL, Price PA, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 112: 275-285, 2008. 86. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365:119–126. 87. Salamon J, Hoffmann T, Elies E, Peldschus K, Johansen JS, Lüers G, Schumacher U, Wicklein D. Antibody Directed against Human YKL-40 Increases Tumor Volume in a Human Melanoma Xenograft Model in Scid Mice. PLoS One 9, 2014. 88. Salavatifar M, Amin S, Jahromi ZM, Rasgoo N, Rastgoo N, Arbabi M. Green fluorescent-conjugated anti-CEA single chain antibody for the detection of CEA-positive cancer cells. Hybridoma (Larchmt) 30: 229-238, 2011. Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 26: 641-648,2005. 89. Schmidt, H.; Johansen, J.S.; Sjoegren, P.; Christensen, I.J.; Sørensen, B.S.; Fode, K.; Larsen, J.; von der Maase, H. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J. Clin. Oncol. 24, 798–804, 2006. 90. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106: 1130-1139, 2006.. 91. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and I melanoma. J Clin Oncol 24: 798-804, 2006b. 92. Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz MK, Hollander NH, Wojdemann M, Bojesen SE, Nielsen KR, Johansen JS. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients withPancreatic Cancer. PLoS One 8: e67059, 2013. 93. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparinbinding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270, 1995. 94. Shadidi M, Sioud M. An anti-leukemic single chain Fv antibody selected from a synthetic human phage antibody library. Biochem Biophys Res Commun 280: 548-552, 2001. 95. Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer 105: 1203-1209, 2011. 96. Shao R, Francescone R, Ngernyuang N, Bentley B, Taylor SL, Moral L, Yan W. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis 35: 373-382, 2014. 97. Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28:4456–4468. 98. Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendroi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rubben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol 32: 663-669, 2014. 99. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62:4364–8, 2002. 100. Teske E. Canine malignant lymphoma: A review and comparison with human non hodgkin's lymphoma. Vet Quart 16: 209-219, 1994. 101. Verhoeckx KCM, Bijlsma S, De Groene EM et al.: A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkes for macrophage maturation in the U937 cell line. Proteomics4,2004;1014–1028. 102. Volck, B.; Johansen, J.S.; Stoltenberg, M.; Garbarsch, C.; Price, P.A.; Østergaard, M.; Østergaard, K.; Løvgreen-Nielsen, P.; Sonne-Holm, S.; Lorenzen, I. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthr. Cartil. 2001, 9, 203–214. 103. Vail DM, Macewen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-792, 2000. 104. Vail DM, Michels GM, Khanna C, et al and the Veterinary Co-operative Oncology Group: Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0): A Veterinary 105. Von Euler HP, Rivera P, Aronsson AC, et al: Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity—evaluation of a new, fully automated nonradiometric assay, Int J Oncol 34:505–510, 2009. 106. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94: 1494-1503, 2002. 107. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, Bindslev L, Haack-Sorensen M, Jorgensen E, Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 42, 2008. 108. Wang ZD, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3 ' to 5 ' exonuclease activity. Journal of Immunological Methods 233: 167-177, 2000. 109. Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 9: e96384, 2014. 110. Yusakul G, Sakamoto S, Pongkitwitoon B, Tanaka H, Morimoto S. Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity. Bioscience, Biotechnology, and Biochemistry 80: 1306-1312, 2016. 111. Zhang Y, Gong Y, Hu D, Zhu P, Wang N, Zhang Q, Wang M, Aldeewan A, Xia H, Qu X, Ring BZ, Minato N, Su L. Nuclear SIPA1 activates integrin beta1 promoter and promotes invasion of breast cancer cells. Oncogene 34: 1451- 1462, 2015. 112. Zheng X, Xing S, Liu XM, Liu W, Liu D, Chi PD, Chen H, Dai SQ, Zhong Q, Zeng MS, Liu WL. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma. BMC Cancer 14: 490, 2014. 113. Zheng JL, Lu L, Hu J, et al. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis 210: 590–595, 2010. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21394 | - |
| dc.description.abstract | YKL-40又稱為CHI3L1 (chitinase-3-like-1) 蛋白，是一種分泌型的醣蛋白，具有幾丁質酶樣結構和幾丁質結合之親和力，但缺乏幾丁質酶活性。人類的YKL-40被認為是一種促炎反應及與腫瘤相關性的蛋白，在人類癌症醫學的研究中發現病患若有升高的血漿/血清YKL-40則會有較低的生存率或不良的預後，這表明YKL-40可能是一種潛在的腫瘤生物標誌，可當作診斷、風險評估和預後的指標。為了研究YKL-40在犬癌症的作用，我們先前的研究已經揭示犬重組YKL-40蛋白 (rcYKL-40) 具有與人類YKL-40相似的生物功能，隨後透過融合瘤技術開發了抗rcYKL-40的小鼠單株抗體，並將其轉變成單鏈變異區片段抗體 (scFv Abs)；有了先前研究的基礎，本研究的目的是在評估癌症犬的組織/血清中YKL-40的表現量，以探討其與癌症病程的相關性。首先，我們將純化的過程加以優化，以獲得高純度及高產量的rcYKL-40，之後以rcYKL-40和scFv Ab建立定量ELISA來偵測血清YKL-40的量；從國立臺灣大學附設動物醫院及地方動物醫院收集21隻健康犬及17隻癌症犬的血清做綜合調查，隨後也追蹤15隻淋巴癌患犬其治療前、治療中和治療後血清中YKL-40的量；另為了評估腫瘤組織中YKL-40的表現量，本實驗以商品化的抗人類YKL-40抗體建立免疫組織化學染色（IHC），評估由臺灣動藥國際股份有限公司所提供的38個犬黑素細胞瘤和23個犬肥大細胞腫瘤之石蠟包埋組織中YKL-40的表現量。研究結果發現癌症犬血清中YKL-40的量 (中位數=8.6450) 顯著高於健康犬血清中YKL-40的量 (中位數=1.8335)，同時血清中YKL-40量的變化與淋巴癌患犬的治療反應有密切關聯，其中治療後腫瘤消退時血清YKL-40量會顯著下降 (p=0.0013)，若後續腫瘤再轉變為惡性進展則血清YKL-40量會顯著上升 (p=0.0037)。在腫瘤組織中，YKL-40的表現量與黑素瘤的惡性程度有關，其中相較於良性黑素細胞瘤和皮膚型惡性黑色素瘤，粘膜型和趾間型的惡性黑素瘤會表現較高量的YKL-40 (p=0.0042)；而在肥大細胞腫瘤中，雖然YKL-40的表現在腫瘤分級間沒有顯著差異 (p=0.2921)，但我們觀察到YKL-40在腫瘤組織周邊的腫瘤細胞染色強度高於中心區域，此染色強度的區別顯示YKL-40可能在肥大細胞腫瘤局部的細胞侵潤過程發揮作用。根據我們研究的結果，犬YKL-40在血液和組織中的量或許可以作為評估癌症的惡性程度及預後良惡的指標。 | zh_TW |
| dc.description.abstract | YKL‐40, also known as CHI3L1 (chitinase-3-like-1), is a secretory glycoprotein and belongs to the mammalian chitinase‐like proteins with chitinase like structure and chitin-binding affinity, but lacking chitinase activity. Human YKL-40 was considered to be a proinflammatory and tumor-associated protein. Several studies indicated that elevated levels of plasma/serum YKL-40 were related to poor survival and poor prognosis in various human cancers, suggesting that YKL-40 might serve as a potential bio-marker of diagnosis, risk assessment, and prognosis factor for tumors. To investigate the role of YKL-40 in dogs, our previous studies have successfully expressed and purified recombinant canine YKL-40 (rcYKL-40) which revealed similar bio-functions with human YKL-40. Inspired by this, our lab has developed mouse monoclonal antibodies against rcYKL-40 through hybridoma technology and generated, subsequently, single-chain variable fragment antibodies (scFv Abs). Based on our previous results, the aims of this study are to investigate the correlation of tissue/serum YKL-40 levels and tumor progression in canine cancers. First, we optimized the process of purification and successfully gained high yield and high purity of rcYKL-40. To evaluate the YKL40 levels in serum, our rcYKL40 and scFv Abs were used to establish a quantitative ELISA. The serum samples of healthy dogs (n=21) and cancer dogs (n=17) were collected from National Taiwan University Veterinary Hospital and local animal hospitals. Furthermore, lymphoma dogs (n=15) were kept monitoring the serum YKL-40 levels by before, during and after treatment. In addition, a rabbit polyclonal anti-human YKL-40 antibody was used to establish immunohistochemical staining for evaluating YKL-40 levels in tumor tissues. Paraffin embedded tissue blocks of canine melanocytic neoplasms (n=38) and mast cell tumors (n=23) were provided by the Histopathology Service Section of Vetco Pharmaceuticals Inc. Our results indicated that serum YKL-40 levels in cancer dogs (median=8.6450) are significantly higher than that in healthy dogs (median=1.8335). The alternation of serum YKL-40 levels was significantly related to the treatment response in lymphoma dogs. The levels significantly decreased in the response of remission (p=0.0013), and the levels significantly elevated when the progression was noted (p=0.0037) afterwards. Canine YKL-40 expression is associated with tumor malignancy in melanocytic neoplasms, which the mucosal and digital malignant melanoma have significant YKL-40 overexpression than benign melanocytoma and cutaneous melanoma (p=0.0042). Although there was no significant difference of YKL-40 overexpression among different grade of mast cell tumors (p=0.2921), YKL-40 was observed that the tumors cell in the tumor margin had stronger staining intensity than those in the central area. This staining pattern indicated YKL-40 may play a role in local invasion of tumor cells in MCT. In accordance with our results, the YKL-40 levels in tissue and blood may be a potential indicator for assessing malignancy and prognosis in canine cancers. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T03:32:52Z (GMT). No. of bitstreams: 1 ntu-108-R06629011-1.pdf: 2657737 bytes, checksum: b5f5fd716042a15904d617923745c106 (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | 中文摘要 I
Abstract III Nomenclature VI Chapter 1. Background and Literature Reviews 1 1.1 YKL-40 in human research 1 1.1.1 The regulations of YKL-40 in cancer cell 2 1.1.2 The prognosis value of YKL-40 in cancer 2 1.1.3 The predicted or monitoring value of YKL-40 in cancer 3 1.1.4 The correlation of YKL-40 in non-cancer disease 4 1.2 Canine lymphoma 4 1.2.1 Incidence and predilection 5 1.2.2 Treatment response evaluation 5 1.3 Canine mast cell tumor 6 1.3.1 Incidence and predilection 6 1.3.2 Histological classification 7 1.4 Canine melanocytic neoplasms 7 1.4.1 Incidence and predilection 7 1.4.2 Histological classification 8 Chapter 2. Introduction 10 Chapter 3. Materials and Methods 13 3.1 Cell cultures 13 3.2 Expression and purification of recombinant canine YKL-40 protein 13 3.3 Expression and purification of recombinant scFv proteins 14 3.4 Western blot analysis 15 3.5 Migration assay 16 3.6 Invasion assay 16 3.7 Healthy and cancer dogs serum collection 17 3.8 Serum YKL-40 levels detection by quantitative ELISA 18 3.9 Tumor tissues collection and histological evaluation 19 3.10 Immunohistochemistry 20 3.11 Statistical analysis 21 Chapter 4. Results 23 4.1 Preparation of rcYKL-40 protein and scFv Abs 23 4.1.1 Purification of rcYKL-40 protein 23 4.1.2 Identification of rcYKL-40 and scFv Abs by Western blot analysis 23 4.2 The biological functions induced by rcYKL-40 protein purified from CL2436 24 4.2.1 Invasion assay 24 4.2.2 Migration assay 25 4.3 Detection of serum YKL-40 levels by quantitative ELISA 26 4.3.1 YKL-40 quantitative ELISA was established by using scFv/M2 and rcYKL-40 26 4.3.2 Serum YKL-40 levels elevated in cancer dogs 26 4.3.3 Serum YKL-40 levels was related to the clinical response of treatment in canine lymphoma 27 4.4 Measurements of YKL-40 expression by IHC 28 4.5 Detected YKL-40 expression in canine Mast cell tumor (MCT) tissues by IHC 29 4.5.1 Tissue collection and diagnosis 29 4.5.2 MCTs tissue expressed YKL-40 29 4.5.3 YKL-40 overexpression of MCTs have no significant difference in both characteristics and tumor grading 30 4.6 Detected YKL-40 expression in canine melanocytic neoplasm tissues by IHC 30 4.6.1 Tissue collection and diagnosis 30 4.6.2 Melanocytoma and melanoma tissue expressed YKL-40 31 4.6.3 YKL-40 overexpression in Melanocytic neoplasms were corresponded to tumor malignancy 32 Chapter 5. Discussion 33 Tabels 48 Table 1. Signalments of cancer dog serum samples for qELSA 48 Table 2. Measures of response in cancer therapy and treatment, RECIST 49 Table 3. Signalments of MCTs tissues for IHC 50 Table 4. Signalments of melanocytoma and cutaneous melanoma for IHC 51 Table 5. Signalments of digital and mucosal melanoma for IHC 52 Figures 53 Figure 1. The fraction analysis of different rcYKL-40 purified process by 10% SDS-PAGE. 53 Figure 2. Identification of purified rcYKL-40 and scFv Abs by Western blot. 55 Figure 3. Invasion assay of CM01 and UCDK9M5. 56 Figure 4. Migration assay of CM01 and UCDK9M5. 57 Figure 5. Establishment of quantitative ELISA for serum YKL-40 detection. 58 Figure 6. Detection of healthy and cancer dog serum YKL-40 levels by quantitative ELISA. 59 Figure 7. The alternations of serum YKL-40 levels in 3 lymphoma dogs from tracing before treatment to remaining in complete remission (rCR). 60 Figure 8. The alternations of serum YKL-40 levels in 4 lymphoma dogs with progressive disease. 61 Figure 9. Detection of serum YKL-40 levels with treatment response in lymphoma dogs by quantitative ELISA. 63 Figure 10. IHC staining sections were assessed by a quick-score method. 64 Figure 11. IHC staining of YKL-40 in canine MCT tissues. 65 Figure 12. Correlation between YKL-40 overexpression with characteristics and pathology grading of canine MCTs by Pearson's chi-square test. 66 Figure 13. IHC staining of YKL-40 in canine melanocytic neoplasm tissues. 68 Figure 14. Correlation of YKL-40 overexpression with characteristics and pathology classification of canine melanocytic neoplasms by Pearson's chi-square test. 69 Figure 15. Purity and yield of rcYKL-40 from CL7208 and CL2436. 71 Figure 16. Detection of rcYKL-40 and serum by sandwich ELISA 72 Figure 17. Comparison of YKL-40 levels between serum and plasma of same dog. 74 Figure 18. Serum YKL-40 levels may be an early preditor for cancer. 75 Figure 19. The alterations of serum YKL-40 levels before and after treatment of canine MCT. 76 Figure 20. Comparison of serum YKL-40 levels in canine cancers with other canine diseases. 77 Figure 21. IHC staining of canine YKL-40 in MGT tissues with scFv Ab. 78 Figure 22. YKL-40 produced by other nontumor cells. 80 Figure 23. Highly expressed YKL-40 was found in invading tumor cells of canine MCT tissue. 82 Figure 24. Canine YKL-40 expression in MGT 84 Reference 85 | |
| dc.language.iso | zh-TW | |
| dc.title | 癌症患犬血清/組織YKL-40表現量與癌症病程的關聯性 | zh_TW |
| dc.title | Correlation between serum/tissue YKL-40 levels
and tumor progression in cancer dogs | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李繼忠,黃威翔,林辰栖 | |
| dc.subject.keyword | YKL-40,犬隻,癌症,定量酵素免疫分析法,組織免疫化學染色, | zh_TW |
| dc.subject.keyword | YKL-40,canine,cancer,enzyme-linked immunosorbent assay (ELISA),immunohistochemistry (IHC), | en |
| dc.relation.page | 93 | |
| dc.identifier.doi | 10.6342/NTU201902763 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2019-08-08 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-1.pdf 未授權公開取用 | 2.6 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。